Graph takes few seconds to load...
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines.
Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer.
The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers.
Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
| Annual Data | Millions of US $ except per share data |
|---|
| Cash on hand |
| Receivables |
| Inventory |
| Pre-Paid Expenses |
| Other Current Assets |
| Total Current Assets |
| Property, Plant, And Equipment |
| Long-Term Investments |
| Goodwill And Intangible Assets |
| Other Long-Term Assets |
| Total Long-Term Assets |
| Total Assets |
| Total Current Liabilities |
| Long Term Debt |
| Other Non-Current Liabilities |
| Total Long Term Liabilities |
| Total Liabilities |
| Common Stock Net |
| Retained Earnings (Accumulated Deficit) |
| Comprehensive Income |
| Other Share Holders Equity |
| Share Holder Equity |
| Total Liabilities And Share Holders Equity |
